Adenosine receptors as therapeutic targets

By Kenneth A. Jacobson, Zhang-Guo Gao. Nature reviews. Drug discovery, 2006

1,407 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Immune cell regulation by autocrine purinergic signalling (2011, background): “Compared to the P2 receptors, a much wider selection of powerful and specific drugs is available for the modulation of adenosine receptor”
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases (2006, background): “However, it is now known to be also linked to various kinase pathways including protein kinase C (PKC), phosphoinositide 3 (PI3) kinase and mitogen-activated protein (MAP) kinase”
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update (2011, background): “Selective agonists and antagonists for all four adenosine receptor subtypes are available (Müller, 2000a,b; Yan et al., 2003; Jacobson and Gao, 2006; Müller and Ferré, 2007; Elzein and Zablocki, 2008; Müller and Jacobson, 2011).”
Approaches to efficiently estimate solvation and explicit water energetics in ligand binding: the use of WaterMap (2013, positive): “[74] mapped the hydration sites and studied the thermodynamic profiles for the GPCR adenosine A2A (A2A) receptor [75] in order to explain the interesting and confusing SARs between triazolylpurine analogs and the A2A receptor [76].”